A61K31/197

MIXTURE OF CARBOXYLIC ACIDS FOR TREATING PATIENTS WITH KIDNEY FAILURE

Our invention is a mixture of carboxylic acids: citric acid, succinic acid, fumaric acid and malic acid, and any possible combinations thereof. This product is used orally or also intravenously, in the treatment of patients with chronic renal failure, hyperammonemia or human conditions having negative nitrogen balance. This product is beneficial in decreasing the serum values of urea and serum ammonium, while promoting by transamination of the oxalacetate formed via succinate, fumarate and malate, the biosynthesis of non-essential amino acids; by transamination of the alpha ketoglutarate formed via citrate, it generates glutamic acid and related amino acids such as glutamine. This treatment prevents, preserves and even improves kidney function. In other patients it delays deterioration of renal function and the urgent need for renal replacement therapy. In others, it is used as a supplemental renal replacement treatment to improve the patient's quality of life and improve laboratory parameters.

COMPOSITIONS COMPRISING MAGNOLIA, PHELLODENDRON, THEANINE AND/OR WHEY PROTEIN
20180000766 · 2018-01-04 ·

An anxiolytic composition includes a synergistic combination of one or more of an extract of magnolia, an extract of phellodendron, an L-theanine, a whey protein composition, and/or an s-adenosylmethionine (SAMe).

COMPOSITIONS COMPRISING MAGNOLIA, PHELLODENDRON, THEANINE AND/OR WHEY PROTEIN
20180000766 · 2018-01-04 ·

An anxiolytic composition includes a synergistic combination of one or more of an extract of magnolia, an extract of phellodendron, an L-theanine, a whey protein composition, and/or an s-adenosylmethionine (SAMe).

PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING DISEASE CAUSED BY CORONAVIRUS AND/OR ROTAVIRUS

The present invention provides a pharmaceutical composition for prevention and/or treatment of diseases induced by viruses of genus coronavirus and/or genus rotavirus. The pharmaceutical composition includes the following components by weight percent: 0.5-100% of taurine, 0-85% of a vitamin complex, and 0-15% of a flavoring agent.

Food supplement, uses thereof, method for food supplementation, and oral spray

The invention relates to a food supplement containing minerals and/or vitamins, a humectant and, for example, essential oils. The food supplement is formulated as an oral spray. In particular, the invention relates to a concentrated food supplement in the form of an oral spray, containing a combination of magnesium ions, panthenol (vitamin B5), caffeine, menthol aroma and/or peppermint aroma, and a humectant. The food supplement is particularly suited for use in sport and in stressful situations.

Food supplement, uses thereof, method for food supplementation, and oral spray

The invention relates to a food supplement containing minerals and/or vitamins, a humectant and, for example, essential oils. The food supplement is formulated as an oral spray. In particular, the invention relates to a concentrated food supplement in the form of an oral spray, containing a combination of magnesium ions, panthenol (vitamin B5), caffeine, menthol aroma and/or peppermint aroma, and a humectant. The food supplement is particularly suited for use in sport and in stressful situations.

METHODS AND COMPOSITIONS FOR REDUCING DAMAGE ASSOCIATED WITH OXIDATIVE PHOSPHORYLATION
20180008573 · 2018-01-11 ·

A composition for reducing damage associated with oxidative phosphorylation. The composition comprises an upregulating compound mixture configured to upregulate an endogenous antioxidant system, an exogenous antioxidant mixture configured to inhibit oxidation of biomolecules by reactive oxygen species, and a mineral mixture configured to provide one or more cofactors to a endogenous antioxidant enzyme. The endogenous antioxidant system includes a Nrf2 transcription factors that promotes transcription of antioxidant genes.

METHODS AND COMPOSITIONS FOR REDUCING DAMAGE ASSOCIATED WITH OXIDATIVE PHOSPHORYLATION
20180008573 · 2018-01-11 ·

A composition for reducing damage associated with oxidative phosphorylation. The composition comprises an upregulating compound mixture configured to upregulate an endogenous antioxidant system, an exogenous antioxidant mixture configured to inhibit oxidation of biomolecules by reactive oxygen species, and a mineral mixture configured to provide one or more cofactors to a endogenous antioxidant enzyme. The endogenous antioxidant system includes a Nrf2 transcription factors that promotes transcription of antioxidant genes.

METHODS AND COMPOSITIONS FOR REDUCING DAMAGE ASSOCIATED WITH OXIDATIVE PHOSPHORYLATION
20180008573 · 2018-01-11 ·

A composition for reducing damage associated with oxidative phosphorylation. The composition comprises an upregulating compound mixture configured to upregulate an endogenous antioxidant system, an exogenous antioxidant mixture configured to inhibit oxidation of biomolecules by reactive oxygen species, and a mineral mixture configured to provide one or more cofactors to a endogenous antioxidant enzyme. The endogenous antioxidant system includes a Nrf2 transcription factors that promotes transcription of antioxidant genes.

PHARMACEUTICAL COMPOSITION WITH ANALGESIC AND ANTI-INFLAMMATORY ACTIVITY
20180008717 · 2018-01-11 ·

A composition comprising a compound having a formula I:

##STR00001##

wherein T is derivative of a terpene and R is a derivative of a neurotransmitter acids, wherein the neurotransmitter acids are selected form GABA, glycine, and taurine. Pharmaceutical formulations for oral and topical use as analgesics and anti-inflammatories are also provided. A process for preparing the composition and the formulations are also provided.